Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by ANALIAS00on Feb 24, 2021 4:46pm
105 Views
Post# 32650450

RE:RE:RE:I am getting the impression

RE:RE:RE:I am getting the impressionSkeptic ? I cant be skeptical at this point ? I do believe SP should be higher if I compare with Cie in a similar situation as TH. Until phase I results are out, it is not a question of being skeptical. We can only hope and TH do the same. Of course they have more reasons than me to think It will work. But that wont be the first Cie to see their phase I failing. So Who am I to say that pre clinical testing results will be 100% the same in phase I ? Nobody knows. We are hoping. We are speculating. Nothing to do with being skeptical. I fully agree that if phase I works well on human, SP will reflect that proportionnaly to the results. I am positive at that. No skeptical at all. I sure am skeptical about Muslix statement earlier. That I am. You and him and me can only hope. Hope that until phase I results comes out, few things happen:

- TH can be valuated as other similar cie by the market

- Trogarzo and Egrifta sales increase

- TH provide good news on NASH Phase III progress

- New institutions and/or analysts come into play

IF and Only IF everything goes as hopped and planned (phase I positive results, increase in sales, nash phase iii on going,etc) in the next year, I can believe at a SP of 14$. But I am skeptical that it will be at 20$ or more. That you can say I am skeptical. I try to be realistic based on fact. It is not a fact that everything will ended the way you want.
FredTheVoice wrote: Always Analia the skeptic.......

Double ?

With ONCOLOGY and NASH ?

You mean rapidly, like in fast track.......double, and double again....

I know you dont believe in 20$C....

But before 14$C, you aint got a profit here, and it could happen very fast.....

Lets see.....

FTV.


<< Previous
Bullboard Posts
Next >>